Dr. Clay Siegall is the Chief Executive Officer, Chairman of the board, the President and the founder of Seattle Genetics. The firm specializes in the development of the therapy drugs that are applied to various types of diseases that have not shown any mortality improvement in decades. Dr. Clay is an accomplished scientist who has undergone training in cancer therapies. The idea of Dr. Clay building the Seattle Genetics was tied to the scientific innovation, passion for helping patients and the rigorous research in science and drug development practices. As the leader of the Company, Dr. Siegall led to the development of antibody-drug conjugate (ADC) used in the therapy of cancer.
Dr. Clay B. Siegall holds a Bachelor of Science in Zoology from the University of Maryland, and he is also a holder of Ph.D. in genetics from the University of George Washington. Under Dr. Clay Siegall leadership, Seattle Genetics has emerged from a scratch to venturing into multiple strategic licenses for its ADC technology that consists of AbbVie, Genentech, Pfizer, and GlaxoSmithKline, which have generated revenue of more than $ 300 million. The Company grew from a crew of researchers to become one of the most successful cancer research space. The Company’s potential indications in the development of expanding the list of drugs are evident that Seattle Genetics with its existing drug portfolio is well-positioned to develop an industry with authority in the 21st Century.
Seattle Genetics’ technology has widely been embraced and has gained internal and collaborator programs that have given rise to more than 20 ADCs clinics. Through Seattle Genetics’ Dr. Siegall has managed to develop capital raising activities that have given rise to more than $ 675 million through private financings, public and company’s initial public in the year 2001. Dr. Siegall diminishes the fact that the old ways of treating cancer through systematic chemotherapies are no longer useful in the treatment of cancer. He firmly believes that the value and efficacy of the therapies developed will become more evident in the decades to come. He argues that the old treatments will soon be replaced by the development of more effective targeted drugs.